Efficacy and safety of anisodine hydrobromide injection in acute ischemic stroke—a multicenter real-world observational study
Frontiers in Pharmacology · 21.05.2026 · 17
DOI: 10.3389/fphar.2026.1806290 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.05.2026. Verfasst von Tianxiang Lan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of anisodine hydrobromide injection in patients with acute ischemic stroke in a real-world clinical setting.
Design
Multicenter, real-world observational cohort study conducted from April 2018 to December 2021 with 90-day follow-up. Multivariable logistic regression and inverse probability of treatment weighting (IPTW) were applied.
Participants
A total of 4,179 patients aged ≥18 years with acute ischemic stroke admitted within 30 days of onset were included; 2,120 received anisodine hydrobromide and 2,059 received best medical treatment. Exposure Intravenous anisodine hydrobromide injection administered as part of routine clinical care. Outcomes The primary outcome was unfavorable functional outcome (modified Rankin Scale [mRS] 3–6) at 90 days. Secondary outcomes included overall mRS distribution, changes in National Institutes of Health Stroke Scale (NIHSS) scores, hemorrhagic transformation, and 90-day mortality or recurrent stroke.
Results
Unfavorable functional outcome occurred in 14.3% (282/2,120) of the anisodine group versus 20.6% (396/2059) of controls (adjusted OR, 0.63; 95% CI, 0.53–0.74). IPTW analysis confirmed the result (OR, 0.64; 95% CI, 0.51–0.80). The anisodine group had a more favorable mRS distribution (OR, 0.68; 95% CI, 0.61–0.77) and greater NIHSS improvement (mean ΔNIHSS difference = −0.61; 95% CI, −0.79 to −0.43). Hemorrhagic transformation, mortality, and recurrent stroke did not differ significantly between groups.
Conclusion
In this large multicenter cohort conducted in China, anisodine hydrobromide showed a potential association with improved 90-day functional outcomes, with no clear increase in adverse events among patients with acute ischemic stroke. Clinical Trial Registration https://www.chictr.org.cn/ , identifier ChiCTR1900027517.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Lan, T., Cheng, Y., Yang, T., Yan, Y., Cui, J., Jiang, S., & Wu, B. (2026). Efficacy and safety of anisodine hydrobromide injection in acute ischemic stroke—a multicenter real-world observational study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1806290
Vancouver
Lan T, Cheng Y, Yang T, Yan Y, Cui J, Jiang S, et al. Efficacy and safety of anisodine hydrobromide injection in acute ischemic stroke—a multicenter real-world observational study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1806290
BibTeX
@article{Lan2026,
author = {Lan, Tianxiang and Cheng, Yajun and Yang, Tang and Yan, Yuying and Cui, Jingyu and Jiang, Shuai and Wu, Bo},
title = {Efficacy and safety of anisodine hydrobromide injection in acute ischemic stroke—a multicenter real-world observational study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1806290}
}
EUVIMED